Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the call transcript. Glenmark Life Sciences continues to remain a net debt-free company. Strong cash flow generation (INR 98 crores in the recent quarter) and substantial cash & cash equivalents (INR 308 crores as of June 30, 2023) strengthen the balance sheet. Capital expenditure planned is between INR 150 crores to INR 200 crores for the year, mainly funded internally. No discussion or indication of equity fundraising or debt issuance for expansion or other purposes was stated during the call.

Any current/future capex/capital investment/strategic investment?

Glenmark Life Sciences plans calibrated capex of INR 150-200 crores for FY 2023-24. Capex for the recent quarter (Q1 FY24) was INR 35 crores. Focus on accelerating brownfield expansions at Dahej and Ankleshwar to add capacity faster and cost-effectively compared to greenfield projects. Greenfield project at Solapur is ongoing but delayed slightly. Additional capacities are being added at Dahej, Ankleshwar, and Solapur. The company aims to ensure adequate capacity to support growing demand and CDMO projects. Capex is strategic to meet growing business needs and support mid-teens revenue growth

Future growth expectations in sales/revenue/volumes?

Glenmark Life Sciences expects mid-teens growth in revenue for FY '24, supported by improved demand and favorable pricing environment. The company anticipates strong growth momentum in coming quarters, driven by growth in regulated markets, CDMO business, and emerging markets. CDMO business is on an upward trajectory, aiming to cross INR200 crores revenue this year, up from INR120 crores last year, with new projects expected to kick in Q3-Q4. Over a 5-year horizon, CDMO revenue is expected to grow from approx. INR150 crores to about INR600 crores, increasing its contribution to 14-15% of

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences expects strong growth momentum to continue, with mid-teens revenue growth guidance for FY '24. Margins are expected to remain stable to slightly higher, depending on product mix. CDMO business is growing with revenue potentially crossing INR200 crores this year, contributing positively to margins. New molecule launches are anticipated to contribute significantly, with an expected 50% revenue contribution over the next 5 years. Operating leverage from new plant capacities at Dahej, Ankleshwar, and Solapur is expected as utilization improves. R&D expenditure is maintained

Current/ Expected Orderbook/ Pending Orders?

Glenmark Life Sciences has multiple projects in the CDMO pipeline, with two new projects having reached significant milestones and advanced stages of discussion. There are "quite a few" other active discussions for potential CDMO projects, though exact numbers are not specified. Management does not expect to have as many as 10-11 active CDMO projects by FY 2025 but anticipates a gradual increase over the next 2-3 years. For FY 2024, CDMO business is expected to contribute around 8-9% of total revenue, aiming to cross INR 200 crores. One new CDMO project is expected to start contributing signif

Alivus Life Sciences LtdQ1 FY24Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,268.6P/E: 25.0Market Cap: ₹15.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Glenmark Life Sciences expects mid-teens growth in revenue for FY '24, supported by improved demand and favorable pricing environment.
The company anticipates strong growth momentum in coming quarters, driven by growth in regulated markets, CDMO business, and emerging markets.
CDMO business is on an upward trajectory, aiming to cross INR200 crores revenue this year, up from INR120 crores last year, with new projects expected to kick in Q3-Q4.
Over a 5-year horizon, CDMO revenue is expected to grow from approx. INR150 crores to about INR600 crores, increasing its contribution to 14-15% of total revenue.
New molecule launches are expected to play a significant role in overall growth, contributing up to 50% of total revenue incrementally over the next 5 years.
Capacity expansions and regulatory approvals are expected to support sustained volume increases.
Operating margins are expected to remain stable to slightly higher, depending on product mix and raw material pricing.

Margin guidance

Category 3

Glenmark Life Sciences expects strong growth momentum to continue, with mid-teens revenue growth guidance for FY '24.
Margins are expected to remain stable to slightly higher, depending on product mix.
CDMO business is growing with revenue potentially crossing INR200 crores this year, contributing positively to margins.
New molecule launches are anticipated to contribute significantly, with an expected 50% revenue contribution over the next 5 years.
Operating leverage from new plant capacities at Dahej, Ankleshwar, and Solapur is expected as utilization improves.
R&D expenditure is maintained around 3% of sales, supporting pipeline growth and innovation.
The company has generated strong free cash flow, supporting a healthy balance sheet and potential dividends.
External demand recovery and better input cost environment boost profitability prospects.
However, cautious outlook is maintained due to raw material price fluctuations and uncertain macroeconomic factors.

See what Alivus Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned fundraising through debt or equity in the call transcript.
Glenmark Life Sciences continues to remain a net debt-free company.
Strong cash flow generation (INR 98 crores in the recent quarter) and substantial cash & cash equivalents (INR 308 crores as of June 30, 2023) strengthen the balance sheet.
Capital expenditure planned is between INR 150 crores to INR 200 crores for the year, mainly funded internally.
No discussion or indication of equity fundraising or debt issuance for expansion or other purposes was stated during the call.

Order book

Yes

Glenmark Life Sciences has multiple projects in the CDMO pipeline, with two new projects having reached significant milestones and advanced stages of discussion.
There are "quite a few" other active discussions for potential CDMO projects, though exact numbers are not specified.
Management does not expect to have as many as 10-11 active CDMO projects by FY 2025 but anticipates a gradual increase over the next 2-3 years.
For FY 2024, CDMO business is expected to contribute around 8-9% of total revenue, aiming to cross INR 200 crores.
One new CDMO project is expected to start contributing significantly by Q4 FY 2024.
Existing three commercial CDMO projects are stable and expected to continue delivering at current levels.
The company remains cautiously optimistic due to regulatory and market uncertainties.

See what Alivus Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Glenmark Life Sciences plans calibrated capex of INR 150-200 crores for FY 2023-24.
Capex for the recent quarter (Q1 FY24) was INR 35 crores.
Focus on accelerating brownfield expansions at Dahej and Ankleshwar to add capacity faster and cost-effectively compared to greenfield projects.
Greenfield project at Solapur is ongoing but delayed slightly.
Additional capacities are being added at Dahej, Ankleshwar, and Solapur.
The company aims to ensure adequate capacity to support growing demand and CDMO projects.
Capex is strategic to meet growing business needs and support mid-teens revenue growth guidance.

Track Alivus Life Sciences Ltd — get its next earnings analysis in your feed

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life Sciences Ltd

Rev 3Mar 3

See where Alivus Life Sciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life Sciences Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alivus Life Sciences Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season